{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:15:45Z","timestamp":1791476145989,"version":"4.3.4"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000997","name":"Arnold and Mabel Beckman Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000997","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Microbiology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.mib.2023.102334","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T21:48:41Z","timestamp":1686865721000},"page":"102334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Counteracting antibiotic resistance enzymes and efflux pumps"],"prefix":"10.1016","volume":"75","author":[{"given":"Meng","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania J.","family":"Lupoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mib.2023.102334_bib1","unstructured":"Antibiotic Resistance Threats in the United States, 2019; 2019."},{"key":"10.1016\/j.mib.2023.102334_bib2","doi-asserted-by":"crossref","unstructured":"COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022. Edited by Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of Healthcare Quality Promotion. Hyattsville, MD; 2022. https:\/\/dx.doi.org\/10.15620\/cdc:117915.","DOI":"10.15620\/cdc:117915"},{"key":"10.1016\/j.mib.2023.102334_bib3","first-page":"277","article-title":"The antibiotic resistance crisis: Part 1: causes and threats","volume":"40","author":"Ventola","year":"2015","journal-title":"P & T: Peer-Rev J Formul Manag"},{"key":"10.1016\/j.mib.2023.102334_bib4","unstructured":"Global Tuberculosis Report 2022. Edited by. World Health Organization, Geneva; 2022."},{"key":"10.1016\/j.mib.2023.102334_bib5","first-page":"210","article-title":"Nontuberculous mycobacterial pulmonary infections","volume":"6","author":"Johnson","year":"2014","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.mib.2023.102334_bib6","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41579-020-0331-1","article-title":"Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus","volume":"18","author":"Johansen","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.mib.2023.102334_bib7","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1126\/science.8153625","article-title":"Prevention of drug access to bacterial targets: permeability barriers and active efflux","volume":"264","author":"Nikaido","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.mib.2023.102334_bib8","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.molmed.2020.05.001","article-title":"Antibiotic resistance by enzymatic modification of antibiotic targets","volume":"26","author":"Schaenzer","year":"2020","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.mib.2023.102334_bib9","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrmicro3380","article-title":"Molecular mechanisms of antibiotic resistance","volume":"13","author":"Blair","year":"2015","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.mib.2023.102334_bib10","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41579-022-00820-y","article-title":"Molecular mechanisms of antibiotic resistance revisited","volume":"21","author":"Darby","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.mib.2023.102334_bib11","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.tim.2016.06.009","article-title":"Antibiotic adjuvants: rescuing antibiotics from resistance","volume":"24","author":"Wright","year":"2016","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.mib.2023.102334_bib12","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1039\/D2MD00263A","article-title":"The role of adjuvants in overcoming antibacterial resistance due to enzymatic drug modification","volume":"13","author":"El-Khoury","year":"2022","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.mib.2023.102334_bib13","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1021\/acs.chemrev.0c01214","article-title":"The antibiotic resistome: a guide for the discovery of natural products as antimicrobial agents","volume":"121","author":"Hobson","year":"2021","journal-title":"Chem Rev"},{"key":"10.1016\/j.mib.2023.102334_bib14","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1021\/jacsau.2c00532","article-title":"Chemical basis of combination therapy to combat antibiotic resistance","volume":"3","author":"Si","year":"2023","journal-title":"JACS Au"},{"key":"10.1016\/j.mib.2023.102334_bib15","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1039\/C7NP00019G","article-title":"Opportunities for natural products in 21st century antibiotic discovery","volume":"34","author":"Wright","year":"2017","journal-title":"Nat Prod Rep"},{"key":"10.1016\/j.mib.2023.102334_bib16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.mib.2019.10.008","article-title":"Antibiotics: past, present and future","volume":"51","author":"Hutchings","year":"2019","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.mib.2023.102334_bib17","first-page":"195","article-title":"Chapter ten \u2014 oxidative tailoring reactions catalyzed by nonheme iron-dependent enzymes: streptorubin B biosynthesis as an example","volume":"vol 516","author":"Sydor","year":"2012"},{"key":"10.1016\/j.mib.2023.102334_bib18","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1073\/pnas.1922203117","article-title":"Mechanism of proton transfer in class A \u03b2-lactamase catalysis and inhibition by avibactam","volume":"117","author":"Pemberton","year":"2020","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.mib.2023.102334_bib19","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1073\/pnas.54.4.1133","article-title":"Mechanism of action of penicillins: a proposal based on their structural similarity to acyl-D-alanyl-D-alanine","volume":"54","author":"Tipper","year":"1965","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.mib.2023.102334_bib20","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.cell.2014.11.017","article-title":"Beta-lactam antibiotics induce a lethal malfunctioning of the bacterial cell wall synthesis machinery","volume":"159","author":"Cho","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.mib.2023.102334_bib21","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/jac\/dkh050","article-title":"Augmentin \u00ae (amoxicillin\/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent","volume":"53","author":"White","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mib.2023.102334_bib22","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0140-6736(88)90391-1","article-title":"Amoxycillin\/Clavulanate resistant Escherichia coli","volume":"331","author":"Williams","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.mib.2023.102334_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.42.10.2773","article-title":"Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli","volume":"42","author":"Stapleton","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2023.102334_bib24","article-title":"Drug development concerning metallo-\u03b2-lactamases in gram-negative bacteria","volume":"13","author":"Li","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.mib.2023.102334_bib25","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1128\/AAC.00826-13","article-title":"New \u03b2-lactamase inhibitors: a therapeutic renaissance in an MDR world","volume":"58","author":"Drawz Sarah","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2023.102334_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.1092556","article-title":"\u03b2-Lactam potentiators to re-sensitize resistant pathogens: discovery, development, clinical use and the way forward","volume":"13","author":"Narendrakumar","year":"2023","journal-title":"Front Microbiol"},{"key":"10.1016\/j.mib.2023.102334_bib27","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2023.102334_bib28","doi-asserted-by":"crossref","first-page":"9748","DOI":"10.1021\/ja992590a","article-title":"Isoniazid oxidation by Mycobacterium tuberculosis KatG: a role for superoxide which correlates with isoniazid susceptibility","volume":"121","author":"Wengenack","year":"1999","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.mib.2023.102334_bib29","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.meegid.2016.09.004","article-title":"Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis","volume":"45","author":"Unissa","year":"2016","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.mib.2023.102334_bib30","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1016\/j.jmb.2019.02.016","article-title":"The isoniazid paradigm of killing, resistance, and persistence in Mycobacterium tuberculosis","volume":"431","author":"Vilch\u00e8ze","year":"2019","journal-title":"J Mol Biol"},{"key":"10.1016\/j.mib.2023.102334_bib31","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.apsb.2017.05.003","article-title":"Arylamine N-acetyltransferase 2 genotype-dependent N-acetylation of isoniazid in cryopreserved human hepatocytes","volume":"7","author":"Doll","year":"2017","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.mib.2023.102334_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00456-20","article-title":"Acetylation of isoniazid is a novel mechanism of isoniazid resistance in Mycobacterium tuberculosis","volume":"65","author":"Arun","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2023.102334_bib33","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1084\/jem.20031956","article-title":"Arylamine n-acetyltransferase is required for synthesis of mycolic acids and complex lipids in Mycobacterium bovis BCG and represents a novel drug target","volume":"199","author":"Bhakta","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.mib.2023.102334_bib34","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1128\/JB.181.4.1343-1347.1999","article-title":"Cloning and characterization of arylamine N -acetyltransferase genes from mycobacterium smegmatis and Mycobacterium tuberculosis: increased expression results in isoniazid resistance","volume":"181","author":"Payton","year":"1999","journal-title":"J Bacteriol"},{"key":"10.1016\/j.mib.2023.102334_bib35","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1016\/j.bmc.2007.02.011","article-title":"Inhibition of mycobacterial arylamine N-acetyltransferase contributes to anti-mycobacterial activity of Warburgia salutaris","volume":"15","author":"Madikane","year":"2007","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.mib.2023.102334_bib36","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s13238-010-0006-1","article-title":"Identification of arylamine N-acetyltransferase inhibitors as an approach towards novel anti-tuberculars","volume":"1","author":"Westwood","year":"2010","journal-title":"Protein Cell"},{"key":"10.1016\/j.mib.2023.102334_bib37","doi-asserted-by":"crossref","first-page":"16274","DOI":"10.3390\/molecules191016274","article-title":"Exploration of piperidinols as potential antitubercular agents","volume":"19","author":"Abuhammad","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.mib.2023.102334_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics9070368","article-title":"3-(5-Nitrofuran-2-yl)prop-2-en-1-one derivatives, with potent antituberculosis activity, inhibit a novel therapeutic target, arylamine N-acetyltransferase, in mycobacteria","volume":"9","author":"Agre","year":"2020","journal-title":"Antibiotics"},{"key":"10.1016\/j.mib.2023.102334_sbref36","doi-asserted-by":"crossref","DOI":"10.1016\/j.snb.2022.132714","article-title":"Fluorescence-based visual analysis and inhibitor screening of arylamine N-acetyltransferase 2, a key enzyme for tuberculosis","volume":"373","author":"Yan","year":"2022","journal-title":"Sens Actuators B: Chem"},{"key":"10.1016\/j.mib.2023.102334_bib40","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1021\/cr030112j","article-title":"Rifamycin mode of action, resistance, and biosynthesis","volume":"105","author":"Floss","year":"2005","journal-title":"Chem Rev"},{"key":"10.1016\/j.mib.2023.102334_bib41","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1021\/acs.accounts.1c00048","article-title":"The enzymes of the rifamycin antibiotic resistome","volume":"54","author":"Surette","year":"2021","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.mib.2023.102334_bib42","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1126\/science.1120800","article-title":"Sampling the antibiotic resistome","volume":"311","author":"D'Costa","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.mib.2023.102334_bib43","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1574-6968.1987.tb02320.x","article-title":"Rifampicin inactivation by Rhodococcus and Mycobacterium species","volume":"44","author":"Dabbs","year":"1987","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.mib.2023.102334_bib44","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.chembiol.2018.01.009","article-title":"Rox, a rifamycin resistance enzyme with an unprecedented mechanism of action","volume":"25","author":"Koteva","year":"2018","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.mib.2023.102334_bib45","doi-asserted-by":"crossref","first-page":"7102","DOI":"10.1073\/pnas.1402358111","article-title":"A rifamycin inactivating phosphotransferase family shared by environmental and pathogenic bacteria","volume":"111","author":"Spanogiannopoulos","year":"2014","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.mib.2023.102334_bib46","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11343","article-title":"Rifampin phosphotransferase is an unusual antibiotic resistance kinase","volume":"7","author":"Stogios","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.mib.2023.102334_bib47","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1128\/AAC.37.6.1313","article-title":"Inactivation of rifampin by Nocardia brasiliensis","volume":"37","author":"Yazawa","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2023.102334_bib48","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1128\/AAC.01166-12","article-title":"Characterization of a rifampin-inactivating glycosyltransferase from a screen of environmental actinomycetes","volume":"56","author":"Spanogiannopoulos","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2023.102334_bib49","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1128\/AAC.43.1.181","article-title":"ADP-ribosylation as an intermediate step in inactivation of rifampin by a mycobacterial gene","volume":"43","author":"Quan","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2023.102334_bib50","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1128\/AAC.43.4.960","article-title":"Integron-mediated rifampin resistance in Pseudomonas aeruginosa","volume":"43","author":"Tribuddharat","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2023.102334_bib51","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1073\/pnas.0711939105","article-title":"Rifamycin antibiotic resistance by ADP-ribosylation: structure and diversity of Arr","volume":"105","author":"Baysarowich","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.mib.2023.102334_sbref49","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1021\/acsinfecdis.1c00297","article-title":"Modulation of a mycobacterial ADP-ribosyltransferase to augment rifamycin antibiotic resistance","volume":"7","author":"Zheng","year":"2021","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.mib.2023.102334_bib53","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1021\/jm100012m","article-title":"Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic","volume":"53","author":"Ferraris","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.mib.2023.102334_bib54","doi-asserted-by":"crossref","first-page":"9575","DOI":"10.1021\/acs.jmedchem.6b00055","article-title":"An update on poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors: opportunities and challenges in cancer therapy","volume":"59","author":"Wang","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.mib.2023.102334_bib55","doi-asserted-by":"crossref","first-page":"5743","DOI":"10.1016\/j.bmcl.2015.10.079","article-title":"Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering","volume":"25","author":"Johannes","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.mib.2023.102334_bib56","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1021\/acschembio.9b00963","article-title":"Structure-guided design and in-cell target profiling of a cell-active target engagement probe for PARP inhibitors","volume":"15","author":"Howard","year":"2020","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.mib.2023.102334_bib57","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijantimicag.2009.08.011","article-title":"Rifampicin combined regimens for Gram-negative infections: data from the literature","volume":"35","author":"Drapeau","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.mib.2023.102334_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/srep09216","article-title":"Sensitization of Gram-negative bacteria to rifampin and OAK combinations","volume":"5","author":"Jammal","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.mib.2023.102334_bib59","doi-asserted-by":"crossref","first-page":"6074","DOI":"10.1128\/jb.178.20.6074-6077.1996","article-title":"Endogenous ADP-ribosylation of proteins in Mycobacterium smegmatis","volume":"178","author":"Serres","year":"1996","journal-title":"J Bacteriol"},{"key":"10.1016\/j.mib.2023.102334_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021807","article-title":"Catalytic and non-catalytic roles for the mono-ADP-ribosyltransferase Arr in the mycobacterial DNA damage response","volume":"6","author":"Stallings","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.mib.2023.102334_bib61","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nature05630","article-title":"Multiple molecular mechanisms for multidrug resistance transporters","volume":"446","author":"Higgins","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.mib.2023.102334_bib62","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/9780470920541.ch3","article-title":"Efflux pumps of the resistance\u2013nodulation\u2013division family: a perspective of their structure, function, and regulation in Gram-Negative Bacteria","volume":"77","author":"Routh","year":"2011","journal-title":"Adv Enzymol Relat Areas Mol Biol"},{"key":"10.1016\/j.mib.2023.102334_bib63","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev-biophys-051013-022855","article-title":"Bacterial multidrug efflux transporters","volume":"43","author":"Delmar","year":"2014","journal-title":"Annu Rev Biophys"},{"key":"10.1016\/j.mib.2023.102334_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/9780470920541.ch1","article-title":"Structure and mechanism of RND-type multidrug efflux pumps","volume":"77","author":"Nikaido","year":"2011","journal-title":"Adv Enzymol Relat Areas Mol Biol"},{"key":"10.1016\/j.mib.2023.102334_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s43440-020-00160-9","article-title":"Efflux pump inhibitors: new updates","volume":"73","author":"AlMatar","year":"2021","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.mib.2023.102334_bib66","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41579-018-0048-6","article-title":"Multidrug efflux pumps: structure, function and regulation","volume":"16","author":"Du","year":"2018","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.mib.2023.102334_bib67","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/nyas.14239","article-title":"AcrB: a mean, keen, drug efflux machine","volume":"1459","author":"Kobylka","year":"2020","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.mib.2023.102334_bib68","doi-asserted-by":"crossref","first-page":"5853","DOI":"10.1128\/jb.178.20.5853-5859.1996","article-title":"Multidrug efflux pumps of gram-negative bacteria","volume":"178","author":"Nikaido","year":"1996","journal-title":"J Bacteriol"},{"key":"10.1016\/j.mib.2023.102334_bib69","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nature01050","article-title":"Crystal structure of bacterial multidrug efflux transporter AcrB","volume":"419","author":"Murakami","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.mib.2023.102334_bib70","article-title":"An allosteric transport mechanism for the AcrAB-TolC multidrug efflux pump","volume":"6","author":"Wang","year":"2017","journal-title":"eLife"},{"key":"10.1016\/j.mib.2023.102334_bib71","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19397-2","article-title":"Perturbed structural dynamics underlie inhibition and altered efflux of the multidrug resistance pump AcrB","volume":"11","author":"Reading","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.mib.2023.102334_bib72","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1128\/AAC.45.1.105-116.2001","article-title":"Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy","volume":"45","author":"Lomovskaya","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2023.102334_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018547","article-title":"Evaluation of multidrug efflux pump inhibitors by a new method using microfluidic channels","volume":"6","author":"Matsumoto","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.mib.2023.102334_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060666","article-title":"The efflux inhibitor Phenylalanine-Arginine Beta-Naphthylamide (PA\u03b2N) permeabilizes the outer membrane of Gram-Negative bacteria","volume":"8","author":"Lamers","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.mib.2023.102334_bib75","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.bcp.2005.12.008","article-title":"Practical applications and feasibility of efflux pump inhibitors in the clinic \u2014 a vision for applied use","volume":"71","author":"Lomovskaya","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.mib.2023.102334_bib76","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature12300","article-title":"Structural basis for the inhibition of bacterial multidrug exporters","volume":"500","author":"Nakashima","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.mib.2023.102334_bib77","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1073\/pnas.1602472113","article-title":"Molecular basis for inhibition of AcrB multidrug efflux pump by novel and powerful pyranopyridine derivatives","volume":"113","author":"Sjuts","year":"2016","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.mib.2023.102334_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115148","article-title":"Design and synthesis of benzochromene derivatives as AcrB inhibitors for the reversal of bacterial multidrug resistance","volume":"249","author":"Guo","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.mib.2023.102334_bib79","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1021\/acsinfecdis.1c00100","article-title":"Mechanistic duality of bacterial efflux substrates and inhibitors: example of simple substituted cinnamoyl and naphthyl amides","volume":"7","author":"D\u2019Cunha","year":"2021","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.mib.2023.102334_bib80","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1021\/acsinfecdis.1c00281","article-title":"A microbe-derived efflux pump inhibitor of the resistance-nodulation-cell division protein restores antibiotic susceptibility in Escherichia coli and Pseudomonas aeruginosa","volume":"8","author":"Tambat","year":"2022","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.mib.2023.102334_sbref78","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-24151-3","article-title":"Allosteric drug transport mechanism of multidrug transporter AcrB","volume":"12","author":"Tam","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.mib.2023.102334_sbref79","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-27726-2","article-title":"Pyridylpiperazine-based allosteric inhibitors of RND-type multidrug efflux pumps","volume":"13","author":"Pl\u00e9","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.mib.2023.102334_sbref80","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1021\/acs.biochem.0c00417","article-title":"Peptide-based approach to inhibition of the multidrug resistance efflux pump AcrB","volume":"59","author":"Jesin","year":"2020","journal-title":"Biochemistry"},{"key":"10.1016\/j.mib.2023.102334_bib84","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-27146-2","article-title":"Structural and functional analysis of the promiscuous AcrB and AdeB efflux pumps suggests different drug binding mechanisms","volume":"12","author":"Ornik-Cha","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.mib.2023.102334_bib85","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1128\/AAC.37.5.1086","article-title":"Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus","volume":"37","author":"Kaatz","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2023.102334_bib86","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1128\/AAC.37.1.128","article-title":"Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter","volume":"37","author":"Neyfakh","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2023.102334_bib87","doi-asserted-by":"crossref","first-page":"6942","DOI":"10.1128\/jb.172.12.6942-6949.1990","article-title":"Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones","volume":"172","author":"Yoshida","year":"1990","journal-title":"J Bacteriol"},{"key":"10.1016\/j.mib.2023.102334_bib88","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1128\/AAC.38.6.1345","article-title":"Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome","volume":"38","author":"Ng","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2023.102334_bib89","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1128\/AAC.00430-07","article-title":"Efflux-related resistance to norfloxacin, dyes, and biocides in bloodstream isolates of Staphylococcus aureus","volume":"51","author":"DeMarco Carmen","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2023.102334_bib90","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1021\/acs.jmedchem.6b01439","article-title":"Pharmacophore-based repositioning of approved drugs as novel Staphylococcus aureus NorA efflux pump inhibitors","volume":"60","author":"Astolfi","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.mib.2023.102334_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2019.103935","article-title":"Antimicrobial activity and inhibition of the NorA efflux pump of Staphylococcus aureus by extract and isolated compounds from Arrabidaea brachypoda","volume":"140","author":"de Sousa Andrade","year":"2020","journal-title":"Microb Pathog"},{"key":"10.1016\/j.mib.2023.102334_sbref89","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41589-022-00994-9","article-title":"Structural basis for inhibition of the drug efflux pump NorA from Staphylococcus aureus","volume":"18","author":"Brawley","year":"2022","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.mib.2023.102334_bib93","article-title":"Update on the discovery of efflux pump inhibitors against critical priority Gram-Negative bacteria","volume":"12","author":"Compagne","year":"2023","journal-title":"Antibiot Ed"},{"key":"10.1016\/j.mib.2023.102334_bib94","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.00951-21","article-title":"Repurposing approved drugs as fluoroquinolone potentiators to overcome efflux pump resistance in Staphylococcus aureus","volume":"9","author":"Mahey","year":"2021","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.mib.2023.102334_sbref92","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.chembiol.2016.11.011","article-title":"A common platform for antibiotic dereplication and adjuvant discovery","volume":"24","author":"Cox","year":"2017","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.mib.2023.102334_sbref93","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/s41589-022-01119-y","article-title":"A genetic platform to investigate the functions of bacterial drug efflux pumps","volume":"18","author":"Teelucksingh","year":"2022","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.mib.2023.102334_bib97","doi-asserted-by":"crossref","DOI":"10.1186\/s13756-020-00795-6","article-title":"CRISPR-Cas system: a potential alternative tool to cope antibiotic resistance","volume":"9","author":"Aslam","year":"2020","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.mib.2023.102334_bib98","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41564-022-01130-y","article-title":"CRISPRi chemical genetics and comparative genomics identify genes mediating drug potency in Mycobacterium tuberculosis","volume":"7","author":"Li","year":"2022","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.mib.2023.102334_bib99","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1016\/j.cell.2022.05.026","article-title":"BacPROTACs to basics: targeted protein degradation in bacteria","volume":"185","author":"Burslem","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.mib.2023.102334_bib100","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.cell.2022.05.009","article-title":"BacPROTACs mediate targeted protein degradation in bacteria","volume":"185","author":"Morreale","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.mib.2023.102334_bib101","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.669762","article-title":"Applications of bacterial degrons and degraders \u2014 toward targeted protein degradation in bacteria","volume":"8","author":"Izert","year":"2021","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.mib.2023.102334_bib102","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1021\/acsinfecdis.1c00203","article-title":"Targeted protein degradation: the new frontier of antimicrobial discovery?","volume":"7","author":"Powell","year":"2021","journal-title":"ACS Infect Dis"}],"container-title":["Current Opinion in Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1369527423000711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1369527423000711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:59:13Z","timestamp":1761285553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1369527423000711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":102,"alternative-id":["S1369527423000711"],"URL":"https:\/\/doi.org\/10.1016\/j.mib.2023.102334","relation":{},"ISSN":["1369-5274"],"issn-type":[{"value":"1369-5274","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Counteracting antibiotic resistance enzymes and efflux pumps","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mib.2023.102334","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102334"}}